drugset / Trial / NCT02050828
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of AKB-9778 administered as daily subcutaneous injections with and without monthly intravitreal injections of ranibizumab for 3 months in patients with diabetic macular edema.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-04
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AKB-9778 | Unknown | 15 mg | Subcutaneous |
| Subject | Ranibizumab | Monoclonal antibody | 0.3 mg | Intravitreal |